February 25 coronavirus news

By Eoin McSweeney, Hannah Strange and Jessie Yeung, CNN

Updated 0642 GMT (1442 HKT) February 26, 2021
27 Posts
Sort byDropdown arrow
2:13 p.m. ET, February 25, 2021

CDC report suggests 5 patients at Kentucky nursing facility were reinfected with Covid-19

From CNN’s Christopher Rios

Five residents of a skilled nursing facility in Kentucky may have been reinfected with coronavirus in the fall after testing positive for the virus in the summer, a new report from the US Centers for Disease Control and Prevention suggests.

The five residents tested positive for Covid-19 in two separate outbreaks three months apart; the first was in July and the second in October. Each of the five residents, aged 67 to 99, received multiple negative tests between the first and second outbreak, the report said. 

The five patients were asymptotic or only mildly symptomatic during the first outbreak but experienced more severe symptoms during their second infection. During the second outbreak, one of the five patients required hospitalization and eventually died, the report says.

“The finding that all five patients with recurrent COVID-19 had either asymptomatic or mildly symptomatic courses during the first infection is noteworthy, suggesting the possibility that asymptomatic or mildly symptomatic initial infections do not produce sufficiently robust immune response to prevent reinfection,” the report said.

After the first outbreak, weekly testing of all noninfected health care personnel and residents occurred for more than 14 days after the last positive case was identified. And the Kentucky Department of Public Health encouraged the facility to monitor hand hygiene, emphasize environmental cleaning and disinfection, practice universal masking, use standard precautions for general resident content, restrict visitation based on county-level incidence rates, among other precautions. 

“Reinfection risk to the general population is suspected to be low,” the report said. “But SNF residents might have higher risk for new exposures. Based on the observations of this report, testing and cohorting practices in SNFs should not assume that residents infected greater than 90 days earlier are immune to COVID-19.” 

The CDC-led team says the findings support the possibility of reinfection, although there is a possibility some of the earlier tests were false positives. Patients’ samples were not stored, so genomic sequencing could not be performed. 

“The findings also suggest the possibility that disease can be more severe during a second infection,” the report said. 

The report said such facilities should use strategies to reduce coronavirus transmission among residents, including those who have previously had a positive test, and vaccination is key.

A study published in the journal JAMA Internal Medicine this week found that people who tested positive for Covid-19 antibodies were at a decreased risk of coronavirus infection compared with those who tested negative for antibodies, but it noted that more research is needed to determine a causal relationship and for how long protection from antibodies may last. 

2:13 p.m. ET, February 25, 2021

Go There: CNN's Dr. Sanjay Gupta answers your questions about Johnson & Johnson's single-dose Covid-19 vaccine

The US Food and Drug Administration says the single-dose Covid-19 vaccine developed by Johnson & Johnson meets requirements for emergency use, and data confirms it is safe and effective.

The FDA's Vaccines and Related Biological Products Advisory Committee will meet tomorrow and after will make its authorization recommendation to the FDA.

CNN chief medical correspondent Dr. Sanjay Gupta was live in New York, where he took viewers' questions on this vaccine.


1:10 p.m. ET, February 25, 2021

Global coronavirus death toll surpasses 2.5 million

From CNN's Hamdi Alkhshali

Grave diggers push the coffin of a Covid-19 victim before a burial at the Alto de Sao Joao cemetery in Lisbon, Portugal, on February 18.
Grave diggers push the coffin of a Covid-19 victim before a burial at the Alto de Sao Joao cemetery in Lisbon, Portugal, on February 18. Patricia De Melo Moreira/AFP/Getty Images

More than 2.5 million people across the world have died due to coronavirus.

At least 2,500,770 people have died since the beginning of the pandemic, according to Johns Hopkins University data.

The milestone of 2 million global Covid-19 deaths was recorded on Jan. 15.

The US leads with the most deaths followed by Brazil, Mexico, India and the UK.

On Feb. 22, the US surpassed the 500,00 total Covid-19 deaths mark, according to Johns Hopkins University.

At least 112,716,833 Covid-19 cases have been reported globally since the beginning of the pandemic, according to data from Johns Hopkins University.  

11:47 a.m. ET, February 25, 2021

How Dubai plans to work with Emirates airlines to verify passengers' Covid-19 tests

From CNN's John Defterios 

Emirates Airlines airplanes are seen at Dubai International Airport on February 1.
Emirates Airlines airplanes are seen at Dubai International Airport on February 1. Karim Sahib/AFP/Getty Images

Dubai plans to link the IT systems of its health authority with Emirates’ reservation and check-in systems, in order to facilitate the digital verification of air passengers' Covid-19 testing and vaccination data.

In a news release, Emirates said the project will allow for “the efficient sharing, storing and verification of passenger health information related to COVID-19 infection, testing and vaccination, all in a secure and legally compliant manner. The project will commence immediately, with the aim of bringing it to "live" implementation to benefit travellers in the coming months.”

11:30 a.m. ET, February 25, 2021

AstraZeneca CEO "very confident" vaccine yield will improve in second quarter 

From CNN's Chloe Adams

AstraZeneca is "very confident" its Covid-19 vaccine yield will improve in the second quarter, noting that the company could even "catch up" to the supply volumes originally projected, company CEO Pascal Soriot said during an European Union virtual summit Thursday. 

"As our teams learn from each other and improve their knowledge, the yield is increasing," Soriot said. "We are very confident that the year to increase across the network so that's one thing we are working very hard on is improving the yield."

"By Q2, we actually catch up to the volume that we had projected originally to produce. And those sites will be a variety of locations around the world, including the United States and some others," Soriot added.

The AstraZeneca CEO said yields have been lower than expected because some of the company's sites have been slow to ramp up production and because "manufacturing of a vaccine is a very complex biological process."

"I can tell you though that the overwhelming majority of what is manufactured in the EU, including the Netherlands facility, is actually going to be used in the EU supply," Soriot told EU officials during the summit. 

11:23 a.m. ET, February 25, 2021

Moderna CEO says current vaccine numbers "far from indicative" of future production

From CNN's James Frater

Moderna CEO Stéphane Bancel attends the Forbes Healthcare Summit in New York in December 2019.
Moderna CEO Stéphane Bancel attends the Forbes Healthcare Summit in New York in December 2019. Steven Ferdman/Getty Images

Moderna's current vaccine production numbers "are far from indicative" of future production, Moderna CEO Stéphane Bancel said during an EU virtual summit Thursday. 

"The numbers we are producing today are far from indicative of what we can produce in the future," Bancel said. "We expect that the additional capacity investment, which we announced yesterday to drive to up to 1.4 billion doses in 2022 will be helpful."

Bancel noted that some of the delays in Moderna's vaccine delivery are due to the company not having a stockpile of the vaccines, as they attempt to get every dose shipped to its destination country as quickly as possible. 

"In the pandemic every dose is crucial, and we want that dose not to be in a factory or warehouse, but to be in somebody's arm," Bancel said. "So, the doses we make are shipped right away. We have no inventory, which means that any minor setback like a broken pump, or simple human mistake by one other operator can mean less doses produced that hour."

"European supply is one of Moderna’s biggest commitments to date. With this in mind we are constantly refining our processes in manufacturing, finding new efficiencies, and we continue to improve our speed. I am dedicated, as is my team, to delivering on this increasing the delivery commitment," Bancel said.

Bancel added that just yesterday, Moderna shipped the first phases of a trial product – aimed at combatting the coronavirus variant first identified in South Africa – to the US National Institutes of Health.

"As you all know, this is a variant of concern," Bancel said. "So we're very proud that this product has been shipped to start clinical trial very soon in humans."

11:11 a.m. ET, February 25, 2021

These are the latest Covid-19 numbers from the US

From CNN's Amanda Watts

There have been at least 28,338,150 cases of coronavirus in the US since the pandemic began and at least 506,121 people have died from Covid-19, according to Johns Hopkins University's tally of cases in the United States.

So far today, the US reported 2,053 new cases and 231 new deaths.  

At least 88,669,035 vaccine doses have been distributed and at least 66,464,947 total doses of the vaccine have been administered, according to the US Centers for Disease Control and Prevention.

The totals include cases from all 50 states, the District of Columbia and other US territories, as well as repatriated cases.  

You can see the latest Johns Hopkins University numbers here.

10:51 a.m. ET, February 25, 2021

European Health Commissioner says EU's goal is to vaccinate 70% of adults by summer

From CNN's James Frater

Europe's Health Commissioner Stella Kyriakides holds a press conference in Brussels, Belgium, on February 17.
Europe's Health Commissioner Stella Kyriakides holds a press conference in Brussels, Belgium, on February 17. Aris Oikonomou/Pool/AFP/Getty Images

The European Union's goal is to vaccinate 70% of adults in each member state "by the summer," Europe's Health Commissioner Stella Kyriakides said during a virtual summit on Thursday. 

“We are seeing more and more people being vaccinated every day and we are taking decisive action to increase the production, delivery and the rollout of vaccines across the EU. But we are also very aware that we need to vaccinate as quickly as possible," Kyriakides said.

“We set an overall target for member states that they should vaccinate a minimum of 70% of their adult population by the summer, it is an ambitious goal, but it is reachable," she added. “Predictability around the deliveries are essential though for an efficient rollout, and together with the member states we are really working 24/7 and doing everything we can to ensure that companies deliver on our agreements."

“We stand ready to update or to conclude new advanced purchase agreements and are working very closely with manufacturers to address any bottlenecks in production as they appear,” Kyriakides added. 

10:55 a.m. ET, February 25, 2021

Bahrain approves single-dose Johnson & Johnson vaccine for emergency use

From CNN’s Mostafa Salem and Hamdi Alkhshali

An investigational pharmacy technician prepares a dose of the Johnson & Johnson Covid-19 vaccine for a clinical trial in Aurora, Colorado, in December 2020.
An investigational pharmacy technician prepares a dose of the Johnson & Johnson Covid-19 vaccine for a clinical trial in Aurora, Colorado, in December 2020. Michael Ciaglo/Getty Images

Bahrain approved the use of Johnson & Johnson’s single-shot coronavirus vaccine, making it the fifth vaccine authorized for emergency use in the tiny Gulf nation, according to the Bahrain News Agency. 

The vaccine will be available for the elderly, people with chronic diseases and other at-risk groups, the statement said. 

“An in-depth study has been conducted on all documents provided by the producing company on the clinical results of the vaccine, in light of the studies conducted in many countries,” the statement added, quoting the head of the National Health Regulatory Authority Mariam Adhbi Al Jalahma. 

The country of 1.6 million people had previously approved the AstraZeneca vaccine, the Pfizer/BioNTech vaccine, the Sinopharm vaccine and the Sputnik V vaccine.